Diligence memo · auto-generated · as of July 2, 2026
Biostem U.S. Corp
Biostem U.S. Corp looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Biostem U.S. Corp operates in Biotechnology, based in CLEARWATER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Biostem U.S. Corp has raised $126K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $126K on 2011-08-02.
Most recent recorded round closed around 2011-08-02.
Valuation (modeled)modeled
Provath models Biostem U.S. Corp at approximately $7.0M (range $67K–$79M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.36× the median modeled value of Pre-Seed Biotechnology companies in 2010–2012 (132 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 14.9 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 2% of Biotechnology peers (4293 compared).
Modeled value ranks above 14% of those peers.
Closest niche peers: Hygeia Therapeutics, Inc., Act Biotech Inc, Ikonopedia, LLC, Iquum Inc, Koronis Pharma, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.